Di seguito l’elenco delle pubblicazioni scientifiche in cui compare il contributo e/o un riconoscimento a Fondazione Ricerca Molinette. Tutte le pubblicazioni sono disponibili online su PubMed. Per maggiori informazioni su specifiche pubblicazioni o sull’attività di ricerca scientifica sostenuta dalla Fondazione, è possibile scrivere a frm@fondazionericercamolinette.it.

Elenco delle pubblicazioni scientifiche per anno

Molecular dynamics of targeting CD38 in multiple myeloma.
Malavasi F, Faini AC, Morandi F, Castella B, Incarnato D, Oliviero S, Horenstein AL, Massaia M, van de Donk NWCJ, Richardson PG.
British Journal Haematology 2021 Feb 11. doi: 10.1111/bjh.17329. Online ahead of print.PMID: 33570193 (I.F. 5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Comparison of CD38 antibodies in vitro and ex vitro mechanisms of action in multiple myeloma.
Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, Rusbuldt J, Bellew K, Kane C, Van de Donk NWC
Haematology. 2021 Jan 14. doi: 10.3324/haematol.2020.268656. Online ahead of print.PMID: 33440920 (I.F. 5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression.
Costa F, Marchica V, Storti P, Malavasi F, Giuliani N.
Cancers (Basel). 2021 Jan 6;13(2):164. doi: 10.3390/cancers13020164.PMID: 33418913 (I.F. 6.126)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Daratumumab in the treatment of light chain (AL) amyloidosis

Giovanni Palladini, Paolo Milani, F. Malavasi, Gianpaolo Merlini
Cells (2021, in press) (I.F. 4.829)
Contributo della Fondazione Ricerca Molinette: Affiliazione


The key role of NAD+ in anti-tumor immune response: an update
Fabio Morandi, Alberto Leonardo Horenstein, F. Malavasi

Frontiers in Immunology Manuscript ID: 658263 (2021, in press) (I.F. 5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione


Curcio C, Brugiapaglia S, Bulfamante S, Follia L, Cappello P, Novelli F.
The glycolitic pathway as a target for novel onco-immunology therapies in pancreatic cancer.
Molecules, 2021, 26(6), 1642. ; doi.org/10.3390/molecules26061642


Mucciolo G, Curcio C, Roux C, Novelli F. et al.
IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions.
PNAS 2021 Feb 9;118(6):e2020395118. doi: 10.1073/pnas.2020395118.

Mandili G, Curcio C, Bulfamante S, Novelli F. et al.
In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.
Journal for ImmunoTherapy of Cancer 2020;0:e001071. doi:10.1136/jitc-2020-001071


Mandili G, Follia L, Ferrero G, Novelli F. et al.
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients.
Cancers (Basel) 2020 Mar 21;12(3):746. doi: 10.3390/cancers12030746.


Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.
Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.PMID: 33322499 (I.F. 4.829)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O, Belisario DC, Compagno M, Giovinazzo F, Bracci C, Pastorino U, Horenstein A, Malavasi F, Ferracini R, Scala S, Sozzi G, Roz L, Roato I, Bertolini G.
Frontiers in Immunology 2020 Oct 2;11:02168. doi: 10.3389/fimmu.2020.02168. eCollection 2020.PMID: 33123122 (I.F. 5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


The Circular Life of Human CD38: From Basic Science to Clinics and Back.
Horenstein AL, Faini AC, Morandi F, Bracci C, Lanza F, Giuliani N, Paulus A, Malavasi F.
Molecules. 2020 Oct 21;25(20):4844. doi: 10.3390/molecules25204844.PMID: 33096610 (I.F.3.267)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH.
Journal Immunotherapy Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987.PMID: 32847986 (I.F. 10.252)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S.
International Journal Molecular Science. 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129.PMID: 32531894 (I.F.4.556)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A.
Blood Advances 2020 May 26;4(10):2143-2157. doi: 10.1182/bloodadvances.2019001091.PMID: 32421811 (I.F. 4.910)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.
Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, Krishfield S, Malavasi F, Yoon J, Sui SJH, Kyttaris VC, Tsokos GC.
Cell Reports 2020 Jan 7;30(1):112-123.e4. doi: 10.1016/j.celrep.2019.12.014.PMID: 31914379 (I.F.8.109)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, Jachetti E, Ribaldone DG, Caviglia GP, Pastorelli L, De Andrea M, Naviglio S, Lucafò M, Stocco G, Grolla AA, Campolo M, Casili G, Cuzzocrea S, Esposito E, Malavasi F, Genazzani AA, Porta C, Travelli C.
Journal Molecular Medicine (Berl). 2020 Apr;98(4):595-612. doi: 10.1007/s00109-020-01892-0. Epub 2020 Apr 27.PMID: 32338310 (I.F. 4.938)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy.
Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N.
British Journal of Haematology 2020 Aug;190(3):430-436. doi: 10.1111/bjh.16548. Epub 2020 Mar 12.PMID: 32162328 (I.F.5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.
Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F.
Cancers (Basel). 2020 Jan 28;12(2):303. doi: 10.3390/cancers12020303.PMID: 32012891 (I.F.6.126)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Viral arthritis and COVID-19.
Parisi S, Borrelli R, Bianchi S, Fusaro E.
Lancet Rheumatol. 2020 Nov;2(11):e655-e657. doi: 10.1016/S2665-9913(20)30348-9. Epub 2020 Oct 5. PMID: 33043303 Free PMC article. No abstract available.


Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC, Parisi S, Priora M, Sanna S, Peroni CL, Laganà A, D’Avolio A, Fusaro E.
Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0. PMID: 32999362 Free PMC article.


Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement.
Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L.
Cells. 2020 Sep 16;9(9):2106. doi: 10.3390/cells9092106. PMID: 32947843 Free PMC article.


Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
Ditto MC, Parisi S, Varisco V, Talotta R, Batticciotto A, Antivalle M, Gerardi MC, Agosti M, Borrelli R, Fusaro E, Sarzi-Puttini P.
Clin Exp Rheumatol. 2020 Sep 16. Online ahead of print. PMID: 32940216


Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.
Carnevale A, Silva M, Maietti E, Milanese G, Saracco M, Parisi S, Bravi E, De Gennaro F, Arrigoni E, Bodini FC, Fusaro E, Scirè CA, Sverzellati N, Ariani A.
Clin Rheumatol. 2020 Sep 3. doi: 10.1007/s10067-020-05375-y. Online ahead of print. PMID: 32880053


Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP.
Scand J Rheumatol. 2020 Nov;49(6):505-506. doi: 10.1080/03009742.2020.1800083. Epub 2020 Aug 28. PMID: 32856492 No abstract available.


Rheumatic manifestations in inflammatory bowel disease.
Finucci A, Ditto MC, Parisi S, Borrelli R, Priora M, Realmuto C, Fusaro E.
Minerva Gastroenterol Dietol. 2020 Jul 3. doi: 10.23736/S1121-421X.20.02726-9. Online ahead of print. PMID: 32623869


How to manage rheumatic patients during the coronavirus pandemic.
Parisi S, Ditto MC, Finucci A, Fusaro E.
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28. PMID: 32343511 Free article. No abstract available.


Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents.Priora M, Realmuto C, Parisi S, Ditto MC, Borrelli R, Peroni CL, Laganà A, Fusaro E. Minerva Gastroenterol Dietol. 2020 Sep;66(3):280-289. doi: 10.23736/S1121-421X.20.02680-X. Epub 2020 Mar 24. PMID: 32218427


G. Brunetti, DC Belisario, S. Bortolotti, G. Storlino, G. Colaianni, MF Faienza, L. Sanesi, V. Alliod, L. Buffoni, E. Centini, C. Voena, R. Pulito, S. Novello, G. Ingravallo, R. Rizzi, G. Mori, JE Reseland, CF Ware, S. Colucci, R. Ferracini , M. Grano, I. Roato.
LIGHT/TNFSF14 promotes osteolytic bone metastasis in non-small cell lung cancer patients.
J Bone Miner Res. 2020; 35(4):671-680.


G. Brunetti, D.C. Belisario, G. Storlino, G. Colaianni, L. Buffoni, G. Ingravallo, C. F. Ware, S. Colucci, R. Ferracini, M. Grano, I. Roato.
LIGHT as regulator of bone homeostasis during osteolytic bone metastasis formation in non-small cell lung cancer patients,
Bone Reports 2020;13:100656.


Roato, F. Mussano, S. Reano, F. Boriani, A. Margara, R. Ferracini, E. Adriani, O. Sabry, M. Fiorini and P. Fattori.
A Novel Method to Optimize Autologous Adipose Tissue Recovery with Extracellular Matrix Preservation
Processes, 2020;8(1):88.


O. Fortunato, C.D. Belisario, M. Compagno, F. Giovinazzo, C. Bracci, U. Pastorino, A. L. Horenstein, F. Malavasi, R. Ferracini, S. Scala, G. Sozzi, L. Roz, I. Roato, G. Bertolini, CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells.
Front Immunol. 2020;11:02168.

I. Roato, R. Ferracini
Is the adipose-derived mesenchymal stem cell therapy effective for treatment of knee osteoarthritis?
Ann. Transl. Med. 2019;7(suppl 3): S114.


I. Roato, R. Ferracini
Is the adipose-derived mesenchymal stem cell therapy effective for treatment of knee osteoarthritis?
Ann. Transl. Med. 2019;7(suppl 3): S114.


T Genova, S Petrillo, E Zicola, I Roato, R Ferracini, E Tolosano, F Altruda,
The crosstalk between osteodifferentiating stem cells and endothelial cells promotes angiogenesis and bone formation,
Front Physiol 2019;10;1291.


I. Ghobrial , C. Hernández Cruz , A. Garfall , N. Shah, N. Munshi, J. Kaufman L. H. Boise, G. Morgan, V. Adalsteinsson, S. Manier, R. Pillar, F. Malavasi and S. Lonial
Immunotherapy in multiple myeloma: accelerating on the path to the patient.
Clinical Lymphoma, Myeloma and Leukemia Jun;19(6):332-344 2019 (I.F. 2.308)


Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma.
Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH.
Frontiers in Immunology 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. eCollection 2019.PMID: 31552039 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N, Malavasi F.
Frontiers in Immunology 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019.PMID: 31475006 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Novel targets for the treatment of relapsing multiple myeloma.
Giuliani N, Accardi F, Marchica V, Dalla Palma B, Storti P, Toscani D, Vicario E, Malavasi F.
Expert Review in Hematology 2019 Jul;12(7):481-496. doi: 10.1080/17474086.2019.1624158. Epub 2019 Jun 3.PMID: 31125526 Review. (I.F. 2.07)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells.
Morandi F, Marimpietri D, Horenstein AL, Corrias MV, Malavasi F.
Oncoimmunology. 2019 Feb 19;8(5):e1574198. doi: 10.1080/2162402X.2019.1574198. eCollection 2019.PMID: 31069133 (I.F. 5.503)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy.
Horenstein AL, Bracci C, Morandi F, Malavasi F.
Frontiers in Immunology 2019 Apr 24;10:760. doi: 10.3389/fimmu.2019.00760. eCollection 2019.PMID: 31068926 (I.F.5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient.
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S.
Clinical Lymphoma, Myeloma and Leukemia 2019 Jun;19(6):332-344. doi: 10.1016/j.clml.2019.02.004. Epub 2019 Feb 20.PMID: 31023594 Review. (I.F. 2.02)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia.
Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A.
Clinical Cancer Research 2019 Jul 1;25(13):3974-3985. doi: 10.1158/1078-0432.CCR-18-3412. Epub 2019 Apr 2.PMID: 30940652 (I.F. 8.9)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Mechanism of Action of a New Anti-CD38 Antibody: Enhancing Myeloma Immunotherapy.
Malavasi F, Faini AC.
Clinical Cancer Research 2019 May 15;25(10):2946-2948. doi: 10.1158/1078-0432.CCR-19-0260. Epub 2019 Mar 7.PMID: 30846477 (I.F. 8.9)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Leggi l’articolo


Follia L, Ferrero G, Mandili G, Novelli F. et al.
Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers.
Front. Oncol., 27 February 2019 | https://doi.org/10.3389/fonc.2019.00115

I. Schiavoni, C. Scagnolari, AL. Horenstein, P. Leone, A: Pierangeli, F. Malavasi, CM Ausiello and G. Fedele
CD38 modulates respiratory syncytial virus-driven proinflammatory processes in human monocyte-derived dendritic cells.
Immunology: 154(1):122-131, 2018 May (I.F. 4.078)

Leggi l’articolo


N.W.C.J. van de Donk, P.G. Richardson and F. Malavasi
CD38 antibodies in multiple myeloma: back to the future.
Blood 4; 131(1):13-29, 2018 (I.F.13.164)


A.L. Horenstein, A. Chillemi, G. Mesiano, R. Zini, V. Quarona, N. Bianchi, M. Aglietta, G. Grignani, R. Manfredini, R. Gambari, D. Sangiolo, F. Malavasi and D. Ferrari
Cytokine-induced killer cells express CD39, CD38, CD203a, CD73 ectoenzymes and P1 adenosinergic receptors.
Frontiers in Pharmacology 9:196, Aprile 2018 (I.F. 6.429)

Leggi l’articolo


F. Morandi, A.L. Horenstein, R. Rizzo and F. Malavasi
The role of extracellular adenosine generation in the development of autoimmune diseases.
Mediators of Inflammation 7019398, 2018 (I.F. 3.232)


F. Morandi, D. Marimpietri, A.L. Horenstein, M. Bolzoni, D. Toscani, F. Costa, B. Castella, A.C. Faini, M. Massaia, V. Pistoia, N. Giuliani and F. Malavasi
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+.
OncoImmunology 7;7(8):e1458809, Maggio 2018 (I.F. 5.503)


E. Ferrero, A.C. Faini and F. Malavasi
A phylogenetic view of the leukocyte ectonucleotidases.
Immunology Letters, 2018 Review (I.F. 2.436)


F. Morandi, A.L. Horenstein, F. Costa, N. Giuliani, V. Pistoia and F. Malavasi
CD38: a target for immunotherapeutic approaches in multiple myeloma
Frontiers in Immunology 28;9:2722, 2018 (I.F. 6.429)


A.L. Horenstein, F. Morandi, C. Bracci, V. Pistoia and F. Malavasi
Functional Insights into Nucleotide-Metabolizing Ectoenzymes Expressed by Bone Marrow-Resident Cells in Patients with Multiple Myeloma.
Immunology Letters 2018 Nov 14 (I.F. 2.436)

Leggi l’articolo


Ectonucleotidase Expression on Human Amnion Epithelial Cells: Adenosinergic Pathways and Dichotomic Effects on Immune Effector Cell Populations.
Morandi F, Horenstein AL, Quarona V, Faini AC, Castella B, Srinivasan RC, Strom SC, Malavasi F, Gramignoli R.
Journal of Immunology 2019 Feb 1;202(3):724-735. doi: 10.4049/jimmunol.1800432. Epub 2018 Dec 26.PMID: 30587530 (I.F. 4.718)
Contributo della Fondazione Ricerca Molinette

Leggi l’articolo


I. Roato, D.C. Belisario, Compagno M, Verderio L, Sighinolfi A, Mussano F, Genova T, Veneziano F, Pertici G, Perale G, Ferracini R.
Adipose-Derived Stromal Vascular Fraction/Xenohybrid Bone Scaffold: an Alternative Source for Bone Regeneration.
Stem Cells Intl. 2018;Apr 29;4126379. Epub.


Cappello P, Curcio C, Mandili G, Novelli F. et al.
Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners.
Cancers (Basel) 2018 Feb 16;10(2):51. doi: 10.3390/cancers10020051.


Resovi A, Bani MR, Porcu L, Novelli F. et al.
È Soluble stroma-related biomarkers of pancreatic cancer. EMBO Mol Med. 2018 Aug;10(8). pii: e8741. doi: 10.15252/emmm.201708741. PubMed PMID: 29941541; PubMed Central PMCID: PMC6079536.

Borgoni S, Iannello A, Cutrupi S, Allavena P, D’Incalci M, Novelli F, Cappello P. Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.
Oncoimmunology. 2017 Nov 13;7(2):e1393596. doi: 10.1080/2162402X.2017.1393596. eCollection 2018.PMID: 29308326


Roux C, Riganti C, Borgogno SF, Curto R, Curcio C, Catanzaro V, Digilio G, Padovan S, Puccinelli MP, Isabello M, Aime S, Cappello P, Novelli F. Endogenous glutamine decrease is associated with pancreatic cancer progression.
Oncotarget
. 2017 Aug 24;8(56):95361-95376. doi: 10.18632/oncotarget.20545. eCollection 2017 Nov 10. PMID: 29221133


Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM, Roux C, Curcio C, Evangelista A, Allavena P, Salvia R, Rusev B, Scarpa A, Cappello P, Novelli F. FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis.
Oncogene. 2018 Feb 8;37(6):697-709. doi: 10.1038/onc.2017.358. Epub 2017 Oct 23. PMID: 29059164


Principe M, Borgoni S, Cascione M, Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S, Chapelle J, Di Modugno F, Defilippi P, Nisticò P, Cappello P, Riganti C, Leporatti S, Novelli F. Alpha-enolase (ENO1) controls alpha v/beta 3 integrin expression and regulates pancreatic cancer adhesion, invasion, and metastasis. J Hematol Oncol. 2017 Jan 13;10(1):16. doi: 10.1186/s13045-016-0385-8. PMID: 28086938


Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget. 2017 Jan 10;8(2):3274-3288. doi: 10.18632/oncotarget.13712. PMID: 27906678


Cappello P, Principe M, Bulfamante S, Novelli F. Alpha-Enolase (ENO1), a potential target in novel immunotherapies. Front Biosci (Landmark Ed). 2017 Jan 1;22:944-959. doi: 10.2741/4526.
PMID: 27814656


I. Roato, A. Massè, R. Piana, R. Ferracini.
Bone Metastasis from Solid Tumors: Biologic and Clinical State of the Art.
Clin Rev Bone Miner Metab 2017;15:115-122.

I. Roato, D. Alotto, D.C. Belisario, S. Casarin, M. Fumagalli, I. Cambieri, R. Piana, M. Stella, R. Ferracini, C. Castagnoli.
Adipose Derived-Mesenchymal Stem Cells Viability and Differentiating Features for Orthopaedic Reparative Applications: Banking of Adipose Tissue.
Stem Cells Int. 2016;2016:4968724.Epub.


L. D’Amico, C.D. Belisario, G. Migliardi, C. Grange, B. Bussolati, P. D’Amelio, T. Perera, E. Dalmasso, L. Dalle Carbonare, L. Godio, P.M. Comoglio, L. Trusolino, R. Ferracini, I. Roato.
C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.
Oncotarget. 2016;7(29):45525-45537.


Cappello P, Tonoli E, Curto R, Giordano D, Giovarelli M, Novelli F. Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response.
Oncoimmunology. 2015 Dec 21;5(5):e1112940. doi: 10.1080/2162402X.2015.1112940. eCollection 2016 May. PMID: 27467915


Pierobon D, Raggi F, Cambieri I, Pelassa S, Occhipinti S, Cappello P, Novelli F, Musso T, Eva A, Castagnoli C, Varesio L, Giovarelli M, Bosco MC. Regulation of Langerhans cell functions in a hypoxic environment. J Mol Med (Berl). 2016 Aug;94(8):943-55. doi: 10.1007/s00109-016-1400-9. Epub 2016 Mar 10. PMID: 26960761


Capello M, Ferri-Borgogno S, Riganti C, Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello P, Novelli F. Targeting the Warburg effect in cancer cells through ENO1 knockdown rescues oxidative phosphorylation and induces growth arrest. Oncotarget. 2016 Feb 2;7(5):5598-612. doi: 10.18632/oncotarget.6798. PMID: 26734996

Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, Conti L, Bestagno M, Zentilin L, Yang SH, Migliorini P, Cappello P, Burrone O, Novelli F. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells. Oncotarget. 2015 May 10;6(13):11098-113. doi: 10.18632/oncotarget.3572.
PMID: 25860938

Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, Bustreo S, Satolli MA, Pecchioni C, Marchini C, Amici A, Cavallo F, Cappello P, Pierobon D, Novelli F, Giovarelli M. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. Clin Cancer Res. 2014 Jun 1;20(11):2910-21. doi: 10.1158/1078-0432.CCR-13-2663. Epub 2014 Mar 25. PMID: 24668647

2020

Mandili G, Curcio C, Bulfamante S, Novelli F. et al.
In pancreatic cancer, chemotherapy increases antitumor responses to tumor-associated antigens and potentiates DNA vaccination.
Journal for ImmunoTherapy of Cancer 2020;0:e001071. doi:10.1136/jitc-2020-001071

Mandili G, Follia L, Ferrero G, Novelli F. et al.
Immune-Complexome Analysis Identifies Immunoglobulin-Bound Biomarkers That Predict the Response to Chemotherapy of Pancreatic Cancer Patients.
Cancers (Basel) 2020 Mar 21;12(3):746. doi: 10.3390/cancers12030746.

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model.
Zannetti BA, Faini AC, Massari E, Geuna M, Maffini E, Poletti G, Cerchione C, Martinelli G, Malavasi F, Lanza F.
Cells. 2020 Dec 11;9(12):2666. doi: 10.3390/cells9122666.PMID: 33322499 (I.F. 4.829)
Contributo della Fondazione Ricerca Molinette: Affiliazione

CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O, Belisario DC, Compagno M, Giovinazzo F, Bracci C, Pastorino U, Horenstein A, Malavasi F, Ferracini R, Scala S, Sozzi G, Roz L, Roato I, Bertolini G.
Frontiers in Immunology 2020 Oct 2;11:02168. doi: 10.3389/fimmu.2020.02168. eCollection 2020.PMID: 33123122 (I.F. 5.085)
Contributo della Fondazione Ricerca Molinette: Affiliazione

The Circular Life of Human CD38: From Basic Science to Clinics and Back.
Horenstein AL, Faini AC, Morandi F, Bracci C, Lanza F, Giuliani N, Paulus A, Malavasi F.
Molecules. 2020 Oct 21;25(20):4844. doi: 10.3390/molecules25204844.PMID: 33096610 (I.F.3.267)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH.
Journal Immunotherapy Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987.PMID: 32847986 (I.F. 10.252)
Contributo della Fondazione Ricerca Molinette

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.
Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, Barreca A, Malavasi F, Baldovino S.
International Journal Molecular Science. 2020 Jun 10;21(11):4129. doi: 10.3390/ijms21114129.PMID: 32531894 (I.F.4.556)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses.
Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A.
Blood Advances 2020 May 26;4(10):2143-2157. doi: 10.1182/bloodadvances.2019001091.PMID: 32421811 (I.F. 4.910)
Contributo della Fondazione Ricerca Molinette

The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections.
Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, Krishfield S, Malavasi F, Yoon J, Sui SJH, Kyttaris VC, Tsokos GC.
Cell Reports 2020 Jan 7;30(1):112-123.e4. doi: 10.1016/j.celrep.2019.12.014.PMID: 31914379 (I.F.8.109)
Contributo della Fondazione Ricerca Molinette

Neutralization of extracellular NAMPT (nicotinamide phosphoribosyltransferase) ameliorates experimental murine colitis.
Colombo G, Clemente N, Zito A, Bracci C, Colombo FS, Sangaletti S, Jachetti E, Ribaldone DG, Caviglia GP, Pastorelli L, De Andrea M, Naviglio S, Lucafò M, Stocco G, Grolla AA, Campolo M, Casili G, Cuzzocrea S, Esposito E, Malavasi F, Genazzani AA, Porta C, Travelli C.
Journal Molecular Medicine (Berl). 2020 Apr;98(4):595-612. doi: 10.1007/s00109-020-01892-0. Epub 2020 Apr 27.PMID: 32338310 (I.F. 4.938)
Contributo della Fondazione Ricerca Molinette

CD14+ CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy.
Storti P, Vescovini R, Costa F, Marchica V, Toscani D, Dalla Palma B, Craviotto L, Malavasi F, Giuliani N.
British Journal of Haematology 2020 Aug;190(3):430-436. doi: 10.1111/bjh.16548. Epub 2020 Mar 12.PMID: 32162328 (I.F.5.518)
Contributo della Fondazione Ricerca Molinette: Affiliazione

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults.
Lanza F, Maffini E, Rondoni M, Massari E, Faini AC, Malavasi F.
Cancers (Basel). 2020 Jan 28;12(2):303. doi: 10.3390/cancers12020303.PMID: 32012891 (I.F.6.126)
Contributo della Fondazione Ricerca Molinette: Affiliazione

Viral arthritis and COVID-19.
Parisi S, Borrelli R, Bianchi S, Fusaro E.
Lancet Rheumatol. 2020 Nov;2(11):e655-e657. doi: 10.1016/S2665-9913(20)30348-9. Epub 2020 Oct 5. PMID: 33043303 Free PMC article. No abstract available.

Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC, Parisi S, Priora M, Sanna S, Peroni CL, Laganà A, D’Avolio A, Fusaro E.
Sci Rep. 2020 Sep 30;10(1):16178. doi: 10.1038/s41598-020-73183-0. PMID: 32999362 Free PMC article.

Gastric Juice Expression of Th-17 and T-Reg Related Cytokines in Scleroderma Esophageal Involvement.
Nicola S, Rolla G, Bucca C, Geronazzo G, Ridolfi I, Ferraris A, Fusaro E, Peroni CL, Dughera L, Brussino L.
Cells. 2020 Sep 16;9(9):2106. doi: 10.3390/cells9092106. PMID: 32947843 Free PMC article.

Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy.
Ditto MC, Parisi S, Varisco V, Talotta R, Batticciotto A, Antivalle M, Gerardi MC, Agosti M, Borrelli R, Fusaro E, Sarzi-Puttini P.
Clin Exp Rheumatol. 2020 Sep 16. Online ahead of print. PMID: 32940216

Longitudinal change during follow-up of systemic sclerosis: correlation between high-resolution computed tomography and pulmonary function tests.
Carnevale A, Silva M, Maietti E, Milanese G, Saracco M, Parisi S, Bravi E, De Gennaro F, Arrigoni E, Bodini FC, Fusaro E, Scirè CA, Sverzellati N, Ariani A.
Clin Rheumatol. 2020 Sep 3. doi: 10.1007/s10067-020-05375-y. Online ahead of print. PMID: 32880053

Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients.
Bellan M, Parisi S, Stobbione P, Pedrinelli AR, Rizzi E, Casciaro GF, Vassia V, Landi R, Cittone MG, Rigamonti C, Patrucco F, Ditto MC, Finucci A, Realmuto C, Todoerti M, Parodi M, Rossi P, Pirisi M, Fusaro E, Sainaghi PP.
Scand J Rheumatol. 2020 Nov;49(6):505-506. doi: 10.1080/03009742.2020.1800083. Epub 2020 Aug 28. PMID: 32856492 No abstract available.

Rheumatic manifestations in inflammatory bowel disease.
Finucci A, Ditto MC, Parisi S, Borrelli R, Priora M, Realmuto C, Fusaro E.
Minerva Gastroenterol Dietol. 2020 Jul 3. doi: 10.23736/S1121-421X.20.02726-9. Online ahead of print. PMID: 32623869

How to manage rheumatic patients during the coronavirus pandemic.
Parisi S, Ditto MC, Finucci A, Fusaro E.
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28. PMID: 32343511 Free article. No abstract available.

Rheumatologic manifestations of hepatitis C in the era of direct-acting antiviral agents.Priora M, Realmuto C, Parisi S, Ditto MC, Borrelli R, Peroni CL, Laganà A, Fusaro E. Minerva Gastroenterol Dietol. 2020 Sep;66(3):280-289. doi: 10.23736/S1121-421X.20.02680-X. Epub 2020 Mar 24. PMID: 32218427

G. Brunetti, DC Belisario, S. Bortolotti, G. Storlino, G. Colaianni, MF Faienza, L. Sanesi, V. Alliod, L. Buffoni, E. Centini, C. Voena, R. Pulito, S. Novello, G. Ingravallo, R. Rizzi, G. Mori, JE Reseland, CF Ware, S. Colucci, R. Ferracini , M. Grano, I. Roato.
LIGHT/TNFSF14 promotes osteolytic bone metastasis in non-small cell lung cancer patients.
J Bone Miner Res. 2020; 35(4):671-680.

G. Brunetti, D.C. Belisario, G. Storlino, G. Colaianni, L. Buffoni, G. Ingravallo, C. F. Ware, S. Colucci, R. Ferracini, M. Grano, I. Roato.
LIGHT as regulator of bone homeostasis during osteolytic bone metastasis formation in non-small cell lung cancer patients,
Bone Reports 2020;13:100656.

Roato, F. Mussano, S. Reano, F. Boriani, A. Margara, R. Ferracini, E. Adriani, O. Sabry, M. Fiorini and P. Fattori.
A Novel Method to Optimize Autologous Adipose Tissue Recovery with Extracellular Matrix Preservation
Processes, 2020;8(1):88.

O. Fortunato, C.D. Belisario, M. Compagno, F. Giovinazzo, C. Bracci, U. Pastorino, A. L. Horenstein, F. Malavasi, R. Ferracini, S. Scala, G. Sozzi, L. Roz, I. Roato, G. Bertolini, CXCR4 inhibition counteracts immunosuppressive properties of metastatic NSCLC stem cells.
Front Immunol. 2020;11:02168.